Sientra Stock Forecast, Price & News

Sientra (NASDAQ:SIEN) Frequently Asked Questions

Is Sientra a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Sientra in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Sientra stock.
View analyst ratings for Sientra or view top-rated stocks.

How has Sientra's stock price been impacted by Coronavirus?

Sientra's stock was trading at $2.44 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, SIEN shares have increased by 13.9% and is now trading at $2.78.
View which stocks have been most impacted by COVID-19.

When is Sientra's next earnings date?

Sientra is scheduled to release its next quarterly earnings announcement on Thursday, March 10th 2022.
View our earnings forecast for Sientra.

How were Sientra's earnings last quarter?

Sientra, Inc. (NASDAQ:SIEN) announced its quarterly earnings results on Wednesday, November, 10th. The medical instruments supplier reported ($0.08) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.26) by $0.18. The medical instruments supplier had revenue of $19.62 million for the quarter, compared to analysts' expectations of $18.10 million. During the same period in the previous year, the company posted ($0.33) EPS.
View Sientra's earnings history.

What guidance has Sientra issued on next quarter's earnings?

Sientra updated its FY 2021 earnings guidance on Wednesday, December, 8th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $76 million-$78 million, compared to the consensus revenue estimate of $80.95 million.

What price target have analysts set for SIEN?

3 brokers have issued 1 year target prices for Sientra's shares. Their forecasts range from $8.24 to $11.00. On average, they anticipate Sientra's stock price to reach $9.75 in the next twelve months. This suggests a possible upside of 250.6% from the stock's current price.
View analysts' price targets for Sientra or view top-rated stocks among Wall Street analysts.

Who are Sientra's key executives?

Sientra's management team includes the following people:

• Ronald Menezes, President, Chief Executive Officer & Director
• Jeffrey S. Jones, Vice President-Operations
• Andrew C. Schmidt, Chief Financial Officer, Treasurer & Senior VP
• Kim Porter, Vice President-Information Technology
• Denise Dajles, Vice President-Research & Development

Who are some of Sientra's key competitors?

Some companies that are related to Sientra include Eargo (EAR), Sanara MedTech (SMTI), Lakeland Industries (LAKE), United Health Products (UEEC), Conformis (CFMS), Milestone Scientific (MLSS), Surgalign (SRGA), Invacare (IVC), ReWalk Robotics (RWLK), Alpha Pro Tech (APT), Predictive Oncology (POAI), Myomo (MYO), Nutriband (NTRB), Bone Biologics (BBLG) and NanoVibronix (NAOV).
View all of SIEN's competitors.

What other stocks do shareholders of Sientra own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sientra investors own include Rigel Pharmaceuticals (RIGL), Matinas BioPharma (MTNB), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), ADMA Biologics (ADMA), Miragen Therapeutics (MGEN), Corbus Pharmaceuticals (CRBP), Dynavax Technologies (DVAX), Micron Technology (MU) and Novavax (NVAX).

What is Sientra's stock symbol?

Sientra trades on the NASDAQ under the ticker symbol "SIEN."

Who are Sientra's major shareholders?

Sientra's stock is owned by many different retail and institutional investors. Top institutional shareholders include Future Financial Wealth Managment LLC (0.01%). Company insiders that own Sientra stock include Andrew C Schmidt, Andrew C Schmidt, Hove Caroline F Van, Jeffrey M Nugent, Oliver Christian Bennett, Paul Sean Little, Ronald Menezes and Valerie J Miller.
View institutional ownership trends for Sientra.

Which major investors are buying Sientra stock?

SIEN stock was acquired by a variety of institutional investors in the last quarter, including Future Financial Wealth Managment LLC. Company insiders that have bought Sientra stock in the last two years include Andrew C Schmidt, and Ronald Menezes.
View insider buying and selling activity for Sientra or or view top insider-buying stocks.

How do I buy shares of Sientra?

Shares of SIEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Sientra's stock price today?

One share of SIEN stock can currently be purchased for approximately $2.78.

How much money does Sientra make?

Sientra has a market capitalization of $161.58 million and generates $71.24 million in revenue each year. The medical instruments supplier earns $-89.95 million in net income (profit) each year or ($1.86) on an earnings per share basis.

How many employees does Sientra have?

Sientra employs 255 workers across the globe.

What is Sientra's official website?

The official website for Sientra is www.sientra.com.

Where are Sientra's headquarters?

Sientra is headquartered at 420 SOUTH FAIRVIEW AVENUE SUITE 200, SANTA BARBARA CA, 93117.

How can I contact Sientra?

Sientra's mailing address is 420 SOUTH FAIRVIEW AVENUE SUITE 200, SANTA BARBARA CA, 93117. The medical instruments supplier can be reached via phone at (805) 562-3500, via email at [email protected], or via fax at 805-562-8401.